Embree Financial Group Decreases Position in Danaher Co. (NYSE:DHR)

Embree Financial Group lessened its stake in shares of Danaher Co. (NYSE:DHR) by 3.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,414 shares of the conglomerate’s stock after selling 51 shares during the quarter. Embree Financial Group’s holdings in Danaher were worth $325,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. FMR LLC grew its holdings in shares of Danaher by 15.8% during the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after purchasing an additional 3,217,631 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Danaher by 3.0% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock worth $1,417,342,000 after buying an additional 148,251 shares during the last quarter. Fisher Asset Management LLC increased its position in Danaher by 2.6% during the third quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate’s stock worth $1,265,725,000 after buying an additional 116,299 shares during the period. Massachusetts Financial Services Co. MA lifted its stake in Danaher by 17.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after buying an additional 535,254 shares during the last quarter. Finally, Montrusco Bolton Investments Inc. grew its position in shares of Danaher by 30.4% during the third quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock worth $465,617,000 after acquiring an additional 397,671 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Performance

DHR opened at $245.95 on Friday. Danaher Co. has a 1-year low of $225.42 and a 1-year high of $281.70. The stock has a market cap of $177.65 billion, a P/E ratio of 46.94, a P/E/G ratio of 4.43 and a beta of 0.83. The stock’s 50 day simple moving average is $235.33 and its 200 day simple moving average is $253.45. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio is currently 20.61%.

Analysts Set New Price Targets

A number of analysts recently weighed in on DHR shares. Raymond James decreased their price target on shares of Danaher from $300.00 to $275.00 and set an “outperform” rating for the company in a research note on Tuesday, January 21st. Scotiabank began coverage on Danaher in a report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price target on the stock. Guggenheim assumed coverage on Danaher in a research note on Thursday, December 19th. They set a “buy” rating and a $275.00 price objective for the company. UBS Group dropped their target price on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. Finally, Evercore ISI increased their price target on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Six equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $285.55.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.